Latest news

• Sanofi’s new CEO cuts first deal, adding Synthorx for $2.5bn

  squamous cell carcinoma (CSCC). The Regeneron-partnered drug is the first drug in the checkpoint inhibitor class to get a green light in that type of skin cancer, and is also

• Trial backs Inovio/Sanofi combo in hard-to-treat brain cancer

  It could also provide a leap forward for Libtayo, which was approved for cutaneous squamous cell carcinoma (CSCC) in the US in 2018 and in Europe earlier this year, but is

• Dupixent gains can’t keep Sanofi on a growth track

  carcinoma (CSCC) in June. ... Regeneron books sales of Libtayo in the US, where it was approved for CSCC last year, and made $68m from the drug in the first half of the year.

• Dupixent drives Sanofi again, but other new drugs are lagging

  It is too soon to gauge the take-up of Sanofi’s new cancer immunotherapy Libtayo (cemiplimab), which has just been approved for cutaneous squamous cell carcinoma (CSCC) in Europe after

• NICE backs CDF funding for Sanofi/Regeneron’s skin cancer drug Libtayo

  CSCC is “physically and emotionally challenging, and there is a high unmet need for new treatments.”. ... NICE backing bodes well for other reimbursement decisions in Europe, but analysts don’t see the drug making a massive impact despite being on